

# Global Cognitive Decline Treatment Market 2026 by Company, Regions, Type and Application, Forecast to 2032

<https://marketpublishers.com/r/G630B815E3C3EN.html>

Date: June 2026

Pages: 157

Price: US\$ 3,480.00 (Single User License)

ID: G630B815E3C3EN

## Abstracts

According to our (Global Info Research) latest study, the global Cognitive Decline Treatment market size was valued at US\$ 108585 million in 2025 and is forecast to a readjusted size of US\$ 248320 million by 2032 with a CAGR of 7.0% during review period.

Cognitive decline treatment refers to a comprehensive medical intervention system that addresses the decline in memory, attention, executive function, and language abilities caused by aging, neurodegenerative diseases, brain injury, or metabolic diseases. It utilizes a combination of methods, including drug therapy, non-drug interventions, neuromodulation techniques, and digital therapies, to slow or improve the progression of cognitive decline. Its core objectives are to slow disease progression, improve patients' daily living abilities, and enhance their quality of life.

With the accelerating aging of the global population and the rapid increase in the number of people aged 65 and above, the incidence of cognitive decline-related diseases continues to rise, significantly expanding the demand for treatment and intervention. Simultaneously, in drug development, the entry of A $\beta$  monoclonal antibodies into clinical application marks a breakthrough in disease-modifying therapy (DMT). Coupled with the development of digital therapies, AI-based early screening tools, brain-computer interfaces, and neuromodulation technologies, cognitive decline treatment is evolving from single-drug therapy to a comprehensive solution encompassing 'drugs + devices + digital therapies + rehabilitation management.' The market is expected to continue its rapid growth in the future, extending towards early screening, delaying onset, and long-term management.

This report is a detailed and comprehensive analysis for global Cognitive Decline Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

#### Key Features:

Global Cognitive Decline Treatment market size and forecasts, in consumption value (\$ Million), 2021-2032

Global Cognitive Decline Treatment market size and forecasts by region and country, in consumption value (\$ Million), 2021-2032

Global Cognitive Decline Treatment market size and forecasts, by Type and by Application, in consumption value (\$ Million), 2021-2032

Global Cognitive Decline Treatment market shares of main players, in revenue (\$ Million), 2021-2026

#### The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Cognitive Decline Treatment

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Cognitive Decline Treatment market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly and Company, Eisai Co., Ltd, Biogen Inc., Novartis AG, AbbVie Inc., Lundbeck, Takeda Pharmaceutical, Alzheon, TauRx Therapeutics, Medtronic, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

### Market segmentation

Cognitive Decline Treatment market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

### Market segment by Type

Prescription Drugs

Medical Devices

Digital Therapy Software

Rehabilitation Training Services

Others

### Market segment by Intervention Stages

Prevention Stage

Early Intervention

Intermediate Treatment

Late-Stage Supportive Treatment

### Market segment by Technological Pathways

Neurotransmitter Regulation Pathway

Amyloid (A?) Clearance Pathway

Tau Protein Targeting Pathway

Neuroinflammatory Regulation Pathway

Neuroplasticity Enhancement Pathway

#### Market segment by Application

Alzheimer's Disease (AD)

Vascular Cognitive Impairment (VCI)

Parkinson's-Related Cognitive Decline

Post-Traumatic Brain Injury Cognitive Impairment

Mild Cognitive Impairment (MCI)

#### Market segment by players, this report covers

Eli Lilly and Company

Eisai Co., Ltd

Biogen Inc.

Novartis AG

AbbVie Inc.

Lundbeck

Takeda Pharmaceutical

Alzheon

TauRx Therapeutics

Medtronic

Abbott Laboratories

Boston Scientific

NeuroPace

Posit Science

CogniFit

Linus Health

BrainCheck

Eisai

Ono Pharmaceutical

Takeda Pharmaceutical

SK Biopharmaceuticals

VUNO

Ybrain

Green Valley Pharma

Neusoft Medical

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Cognitive Decline Treatment product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Cognitive Decline Treatment, with revenue, gross margin, and global market share of Cognitive Decline Treatment from 2021 to 2026.

Chapter 3, the Cognitive Decline Treatment competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026. and Cognitive Decline Treatment market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Cognitive Decline Treatment.

Chapter 13, to describe Cognitive Decline Treatment research findings and conclusion.

## Contents

### 1 MARKET OVERVIEW

1.1 Product Overview and Scope

1.2 Market Estimation Caveats and Base Year

1.3 Classification of Cognitive Decline Treatment by Type

1.3.1 Overview: Global Cognitive Decline Treatment Market Size by Type: 2021 Versus 2025 Versus 2032

1.3.2 Global Cognitive Decline Treatment Consumption Value Market Share by Type in 2025

1.3.3 Prescription Drugs

1.3.4 Medical Devices

1.3.5 Digital Therapy Software

1.3.6 Rehabilitation Training Services

1.3.7 Others

1.4 Classification of Cognitive Decline Treatment by Intervention Stages

1.4.1 Overview: Global Cognitive Decline Treatment Market Size by Intervention Stages: 2021 Versus 2025 Versus 2032

1.4.2 Global Cognitive Decline Treatment Consumption Value Market Share by Intervention Stages in 2025

1.4.3 Prevention Stage

1.4.4 Early Intervention

1.4.5 Intermediate Treatment

1.4.6 Late-Stage Supportive Treatment

1.5 Classification of Cognitive Decline Treatment by Technological Pathways

1.5.1 Overview: Global Cognitive Decline Treatment Market Size by Technological Pathways: 2021 Versus 2025 Versus 2032

1.5.2 Global Cognitive Decline Treatment Consumption Value Market Share by Technological Pathways in 2025

1.5.3 Neurotransmitter Regulation Pathway

1.5.4 Amyloid (A?) Clearance Pathway

1.5.5 Tau Protein Targeting Pathway

1.5.6 Neuroinflammatory Regulation Pathway

1.5.7 Neuroplasticity Enhancement Pathway

1.6 Global Cognitive Decline Treatment Market by Application

1.6.1 Overview: Global Cognitive Decline Treatment Market Size by Application: 2021 Versus 2025 Versus 2032

1.6.2 Alzheimer's Disease (AD)

- 1.6.3 Vascular Cognitive Impairment (VCI)
- 1.6.4 Parkinson's-Related Cognitive Decline
- 1.6.5 Post-Traumatic Brain Injury Cognitive Impairment
- 1.6.6 Mild Cognitive Impairment (MCI)
- 1.7 Global Cognitive Decline Treatment Market Size & Forecast
- 1.8 Global Cognitive Decline Treatment Market Size and Forecast by Region
  - 1.8.1 Global Cognitive Decline Treatment Market Size by Region: 2021 VS 2025 VS 2032
  - 1.8.2 Global Cognitive Decline Treatment Market Size by Region, (2021-2032)
  - 1.8.3 North America Cognitive Decline Treatment Market Size and Prospect (2021-2032)
  - 1.8.4 Europe Cognitive Decline Treatment Market Size and Prospect (2021-2032)
  - 1.8.5 Asia-Pacific Cognitive Decline Treatment Market Size and Prospect (2021-2032)
  - 1.8.6 South America Cognitive Decline Treatment Market Size and Prospect (2021-2032)
  - 1.8.7 Middle East & Africa Cognitive Decline Treatment Market Size and Prospect (2021-2032)

## **2 COMPANY PROFILES**

- 2.1 Eli Lilly and Company
  - 2.1.1 Eli Lilly and Company Details
  - 2.1.2 Eli Lilly and Company Major Business
  - 2.1.3 Eli Lilly and Company Cognitive Decline Treatment Product and Solutions
  - 2.1.4 Eli Lilly and Company Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
  - 2.1.5 Eli Lilly and Company Recent Developments and Future Plans
- 2.2 Eisai Co., Ltd
  - 2.2.1 Eisai Co., Ltd Details
  - 2.2.2 Eisai Co., Ltd Major Business
  - 2.2.3 Eisai Co., Ltd Cognitive Decline Treatment Product and Solutions
  - 2.2.4 Eisai Co., Ltd Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
  - 2.2.5 Eisai Co., Ltd Recent Developments and Future Plans
- 2.3 Biogen Inc.
  - 2.3.1 Biogen Inc. Details
  - 2.3.2 Biogen Inc. Major Business
  - 2.3.3 Biogen Inc. Cognitive Decline Treatment Product and Solutions
  - 2.3.4 Biogen Inc. Cognitive Decline Treatment Revenue, Gross Margin and Market

## Share (2021-2026)

### 2.3.5 Biogen Inc. Recent Developments and Future Plans

## 2.4 Novartis AG

### 2.4.1 Novartis AG Details

### 2.4.2 Novartis AG Major Business

### 2.4.3 Novartis AG Cognitive Decline Treatment Product and Solutions

### 2.4.4 Novartis AG Cognitive Decline Treatment Revenue, Gross Margin and Market

## Share (2021-2026)

### 2.4.5 Novartis AG Recent Developments and Future Plans

## 2.5 AbbVie Inc.

### 2.5.1 AbbVie Inc. Details

### 2.5.2 AbbVie Inc. Major Business

### 2.5.3 AbbVie Inc. Cognitive Decline Treatment Product and Solutions

### 2.5.4 AbbVie Inc. Cognitive Decline Treatment Revenue, Gross Margin and Market

## Share (2021-2026)

### 2.5.5 AbbVie Inc. Recent Developments and Future Plans

## 2.6 Lundbeck

### 2.6.1 Lundbeck Details

### 2.6.2 Lundbeck Major Business

### 2.6.3 Lundbeck Cognitive Decline Treatment Product and Solutions

### 2.6.4 Lundbeck Cognitive Decline Treatment Revenue, Gross Margin and Market

## Share (2021-2026)

### 2.6.5 Lundbeck Recent Developments and Future Plans

## 2.7 Takeda Pharmaceutical

### 2.7.1 Takeda Pharmaceutical Details

### 2.7.2 Takeda Pharmaceutical Major Business

### 2.7.3 Takeda Pharmaceutical Cognitive Decline Treatment Product and Solutions

### 2.7.4 Takeda Pharmaceutical Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)

### 2.7.5 Takeda Pharmaceutical Recent Developments and Future Plans

## 2.8 Alzheon

### 2.8.1 Alzheon Details

### 2.8.2 Alzheon Major Business

### 2.8.3 Alzheon Cognitive Decline Treatment Product and Solutions

### 2.8.4 Alzheon Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)

### 2.8.5 Alzheon Recent Developments and Future Plans

## 2.9 TauRx Therapeutics

### 2.9.1 TauRx Therapeutics Details

- 2.9.2 TauRx Therapeutics Major Business
- 2.9.3 TauRx Therapeutics Cognitive Decline Treatment Product and Solutions
- 2.9.4 TauRx Therapeutics Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
- 2.9.5 TauRx Therapeutics Recent Developments and Future Plans
- 2.10 Medtronic
  - 2.10.1 Medtronic Details
  - 2.10.2 Medtronic Major Business
  - 2.10.3 Medtronic Cognitive Decline Treatment Product and Solutions
  - 2.10.4 Medtronic Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
  - 2.10.5 Medtronic Recent Developments and Future Plans
- 2.11 Abbott Laboratories
  - 2.11.1 Abbott Laboratories Details
  - 2.11.2 Abbott Laboratories Major Business
  - 2.11.3 Abbott Laboratories Cognitive Decline Treatment Product and Solutions
  - 2.11.4 Abbott Laboratories Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
  - 2.11.5 Abbott Laboratories Recent Developments and Future Plans
- 2.12 Boston Scientific
  - 2.12.1 Boston Scientific Details
  - 2.12.2 Boston Scientific Major Business
  - 2.12.3 Boston Scientific Cognitive Decline Treatment Product and Solutions
  - 2.12.4 Boston Scientific Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
  - 2.12.5 Boston Scientific Recent Developments and Future Plans
- 2.13 NeuroPace
  - 2.13.1 NeuroPace Details
  - 2.13.2 NeuroPace Major Business
  - 2.13.3 NeuroPace Cognitive Decline Treatment Product and Solutions
  - 2.13.4 NeuroPace Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
  - 2.13.5 NeuroPace Recent Developments and Future Plans
- 2.14 Posit Science
  - 2.14.1 Posit Science Details
  - 2.14.2 Posit Science Major Business
  - 2.14.3 Posit Science Cognitive Decline Treatment Product and Solutions
  - 2.14.4 Posit Science Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)

- 2.14.5 Posit Science Recent Developments and Future Plans
- 2.15 CogniFit
  - 2.15.1 CogniFit Details
  - 2.15.2 CogniFit Major Business
  - 2.15.3 CogniFit Cognitive Decline Treatment Product and Solutions
  - 2.15.4 CogniFit Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
  - 2.15.5 CogniFit Recent Developments and Future Plans
- 2.16 Linus Health
  - 2.16.1 Linus Health Details
  - 2.16.2 Linus Health Major Business
  - 2.16.3 Linus Health Cognitive Decline Treatment Product and Solutions
  - 2.16.4 Linus Health Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
  - 2.16.5 Linus Health Recent Developments and Future Plans
- 2.17 BrainCheck
  - 2.17.1 BrainCheck Details
  - 2.17.2 BrainCheck Major Business
  - 2.17.3 BrainCheck Cognitive Decline Treatment Product and Solutions
  - 2.17.4 BrainCheck Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
  - 2.17.5 BrainCheck Recent Developments and Future Plans
- 2.18 Eisai
  - 2.18.1 Eisai Details
  - 2.18.2 Eisai Major Business
  - 2.18.3 Eisai Cognitive Decline Treatment Product and Solutions
  - 2.18.4 Eisai Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
  - 2.18.5 Eisai Recent Developments and Future Plans
- 2.19 Ono Pharmaceutical
  - 2.19.1 Ono Pharmaceutical Details
  - 2.19.2 Ono Pharmaceutical Major Business
  - 2.19.3 Ono Pharmaceutical Cognitive Decline Treatment Product and Solutions
  - 2.19.4 Ono Pharmaceutical Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
  - 2.19.5 Ono Pharmaceutical Recent Developments and Future Plans
- 2.20 Takeda Pharmaceutical
  - 2.20.1 Takeda Pharmaceutical Details
  - 2.20.2 Takeda Pharmaceutical Major Business

- 2.20.3 Takeda Pharmaceutical Cognitive Decline Treatment Product and Solutions
- 2.20.4 Takeda Pharmaceutical Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
- 2.20.5 Takeda Pharmaceutical Recent Developments and Future Plans
- 2.21 SK Biopharmaceuticals
  - 2.21.1 SK Biopharmaceuticals Details
  - 2.21.2 SK Biopharmaceuticals Major Business
  - 2.21.3 SK Biopharmaceuticals Cognitive Decline Treatment Product and Solutions
  - 2.21.4 SK Biopharmaceuticals Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
  - 2.21.5 SK Biopharmaceuticals Recent Developments and Future Plans
- 2.22 VUNO
  - 2.22.1 VUNO Details
  - 2.22.2 VUNO Major Business
  - 2.22.3 VUNO Cognitive Decline Treatment Product and Solutions
  - 2.22.4 VUNO Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
  - 2.22.5 VUNO Recent Developments and Future Plans
- 2.23 Ybrain
  - 2.23.1 Ybrain Details
  - 2.23.2 Ybrain Major Business
  - 2.23.3 Ybrain Cognitive Decline Treatment Product and Solutions
  - 2.23.4 Ybrain Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
  - 2.23.5 Ybrain Recent Developments and Future Plans
- 2.24 Green Valley Pharma
  - 2.24.1 Green Valley Pharma Details
  - 2.24.2 Green Valley Pharma Major Business
  - 2.24.3 Green Valley Pharma Cognitive Decline Treatment Product and Solutions
  - 2.24.4 Green Valley Pharma Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
  - 2.24.5 Green Valley Pharma Recent Developments and Future Plans
- 2.25 Neusoft Medical
  - 2.25.1 Neusoft Medical Details
  - 2.25.2 Neusoft Medical Major Business
  - 2.25.3 Neusoft Medical Cognitive Decline Treatment Product and Solutions
  - 2.25.4 Neusoft Medical Cognitive Decline Treatment Revenue, Gross Margin and Market Share (2021-2026)
  - 2.25.5 Neusoft Medical Recent Developments and Future Plans

### **3 MARKET COMPETITION, BY PLAYERS**

3.1 Global Cognitive Decline Treatment Revenue and Share by Players (2021-2026)

3.2 Market Share Analysis (2025)

3.2.1 Market Share of Cognitive Decline Treatment by Company Revenue

3.2.2 Top 3 Cognitive Decline Treatment Players Market Share in 2025

3.2.3 Top 6 Cognitive Decline Treatment Players Market Share in 2025

3.3 Cognitive Decline Treatment Market: Overall Company Footprint Analysis

3.3.1 Cognitive Decline Treatment Market: Region Footprint

3.3.2 Cognitive Decline Treatment Market: Company Product Type Footprint

3.3.3 Cognitive Decline Treatment Market: Company Product Application Footprint

3.4 New Market Entrants and Barriers to Market Entry

3.5 Mergers, Acquisition, Agreements, and Collaborations

### **4 MARKET SIZE SEGMENT BY TYPE**

4.1 Global Cognitive Decline Treatment Consumption Value and Market Share by Type (2021-2026)

4.2 Global Cognitive Decline Treatment Market Forecast by Type (2027-2032)

### **5 MARKET SIZE SEGMENT BY APPLICATION**

5.1 Global Cognitive Decline Treatment Consumption Value Market Share by Application (2021-2026)

5.2 Global Cognitive Decline Treatment Market Forecast by Application (2027-2032)

### **6 NORTH AMERICA**

6.1 North America Cognitive Decline Treatment Consumption Value by Type (2021-2032)

6.2 North America Cognitive Decline Treatment Market Size by Application (2021-2032)

6.3 North America Cognitive Decline Treatment Market Size by Country

6.3.1 North America Cognitive Decline Treatment Consumption Value by Country (2021-2032)

6.3.2 United States Cognitive Decline Treatment Market Size and Forecast (2021-2032)

6.3.3 Canada Cognitive Decline Treatment Market Size and Forecast (2021-2032)

6.3.4 Mexico Cognitive Decline Treatment Market Size and Forecast (2021-2032)

## **7 EUROPE**

7.1 Europe Cognitive Decline Treatment Consumption Value by Type (2021-2032)

7.2 Europe Cognitive Decline Treatment Consumption Value by Application (2021-2032)

7.3 Europe Cognitive Decline Treatment Market Size by Country

7.3.1 Europe Cognitive Decline Treatment Consumption Value by Country (2021-2032)

7.3.2 Germany Cognitive Decline Treatment Market Size and Forecast (2021-2032)

7.3.3 France Cognitive Decline Treatment Market Size and Forecast (2021-2032)

7.3.4 United Kingdom Cognitive Decline Treatment Market Size and Forecast (2021-2032)

7.3.5 Russia Cognitive Decline Treatment Market Size and Forecast (2021-2032)

7.3.6 Italy Cognitive Decline Treatment Market Size and Forecast (2021-2032)

## **8 ASIA-PACIFIC**

8.1 Asia-Pacific Cognitive Decline Treatment Consumption Value by Type (2021-2032)

8.2 Asia-Pacific Cognitive Decline Treatment Consumption Value by Application (2021-2032)

8.3 Asia-Pacific Cognitive Decline Treatment Market Size by Region

8.3.1 Asia-Pacific Cognitive Decline Treatment Consumption Value by Region (2021-2032)

8.3.2 China Cognitive Decline Treatment Market Size and Forecast (2021-2032)

8.3.3 Japan Cognitive Decline Treatment Market Size and Forecast (2021-2032)

8.3.4 South Korea Cognitive Decline Treatment Market Size and Forecast (2021-2032)

8.3.5 India Cognitive Decline Treatment Market Size and Forecast (2021-2032)

8.3.6 Southeast Asia Cognitive Decline Treatment Market Size and Forecast (2021-2032)

8.3.7 Australia Cognitive Decline Treatment Market Size and Forecast (2021-2032)

## **9 SOUTH AMERICA**

9.1 South America Cognitive Decline Treatment Consumption Value by Type (2021-2032)

9.2 South America Cognitive Decline Treatment Consumption Value by Application (2021-2032)

9.3 South America Cognitive Decline Treatment Market Size by Country

9.3.1 South America Cognitive Decline Treatment Consumption Value by Country (2021-2032)

9.3.2 Brazil Cognitive Decline Treatment Market Size and Forecast (2021-2032)

9.3.3 Argentina Cognitive Decline Treatment Market Size and Forecast (2021-2032)

## **10 MIDDLE EAST & AFRICA**

10.1 Middle East & Africa Cognitive Decline Treatment Consumption Value by Type (2021-2032)

10.2 Middle East & Africa Cognitive Decline Treatment Consumption Value by Application (2021-2032)

10.3 Middle East & Africa Cognitive Decline Treatment Market Size by Country

10.3.1 Middle East & Africa Cognitive Decline Treatment Consumption Value by Country (2021-2032)

10.3.2 Turkey Cognitive Decline Treatment Market Size and Forecast (2021-2032)

10.3.3 Saudi Arabia Cognitive Decline Treatment Market Size and Forecast (2021-2032)

10.3.4 UAE Cognitive Decline Treatment Market Size and Forecast (2021-2032)

## **11 MARKET DYNAMICS**

11.1 Cognitive Decline Treatment Market Drivers

11.2 Cognitive Decline Treatment Market Restraints

11.3 Cognitive Decline Treatment Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

## **12 INDUSTRY CHAIN ANALYSIS**

12.1 Cognitive Decline Treatment Industry Chain

12.2 Cognitive Decline Treatment Upstream Analysis

12.3 Cognitive Decline Treatment Midstream Analysis

12.4 Cognitive Decline Treatment Downstream Analysis

## **13 RESEARCH FINDINGS AND CONCLUSION**

## **14 APPENDIX**

14.1 Methodology

14.2 Research Process and Data Source

14.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. Global Cognitive Decline Treatment Consumption Value by Type, (USD Million), 2021 & 2025 & 2032

Table 2. Global Cognitive Decline Treatment Consumption Value by Intervention Stages, (USD Million), 2021 & 2025 & 2032

Table 3. Global Cognitive Decline Treatment Consumption Value by Technological Pathways, (USD Million), 2021 & 2025 & 2032

Table 4. Global Cognitive Decline Treatment Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Table 5. Global Cognitive Decline Treatment Consumption Value by Region (2021-2026) & (USD Million)

Table 6. Global Cognitive Decline Treatment Consumption Value by Region (2027-2032) & (USD Million)

Table 7. Eli Lilly and Company Company Information, Head Office, and Major Competitors

Table 8. Eli Lilly and Company Major Business

Table 9. Eli Lilly and Company Cognitive Decline Treatment Product and Solutions

Table 10. Eli Lilly and Company Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 11. Eli Lilly and Company Recent Developments and Future Plans

Table 12. Eisai Co., Ltd Company Information, Head Office, and Major Competitors

Table 13. Eisai Co., Ltd Major Business

Table 14. Eisai Co., Ltd Cognitive Decline Treatment Product and Solutions

Table 15. Eisai Co., Ltd Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 16. Eisai Co., Ltd Recent Developments and Future Plans

Table 17. Biogen Inc. Company Information, Head Office, and Major Competitors

Table 18. Biogen Inc. Major Business

Table 19. Biogen Inc. Cognitive Decline Treatment Product and Solutions

Table 20. Biogen Inc. Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 21. Novartis AG Company Information, Head Office, and Major Competitors

Table 22. Novartis AG Major Business

Table 23. Novartis AG Cognitive Decline Treatment Product and Solutions

Table 24. Novartis AG Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 25. Novartis AG Recent Developments and Future Plans

Table 26. AbbVie Inc. Company Information, Head Office, and Major Competitors

Table 27. AbbVie Inc. Major Business

Table 28. AbbVie Inc. Cognitive Decline Treatment Product and Solutions

Table 29. AbbVie Inc. Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 30. AbbVie Inc. Recent Developments and Future Plans

Table 31. Lundbeck Company Information, Head Office, and Major Competitors

Table 32. Lundbeck Major Business

Table 33. Lundbeck Cognitive Decline Treatment Product and Solutions

Table 34. Lundbeck Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 35. Lundbeck Recent Developments and Future Plans

Table 36. Takeda Pharmaceutical Company Information, Head Office, and Major Competitors

Table 37. Takeda Pharmaceutical Major Business

Table 38. Takeda Pharmaceutical Cognitive Decline Treatment Product and Solutions

Table 39. Takeda Pharmaceutical Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 40. Takeda Pharmaceutical Recent Developments and Future Plans

Table 41. Alzheon Company Information, Head Office, and Major Competitors

Table 42. Alzheon Major Business

Table 43. Alzheon Cognitive Decline Treatment Product and Solutions

Table 44. Alzheon Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 45. Alzheon Recent Developments and Future Plans

Table 46. TauRx Therapeutics Company Information, Head Office, and Major Competitors

Table 47. TauRx Therapeutics Major Business

Table 48. TauRx Therapeutics Cognitive Decline Treatment Product and Solutions

Table 49. TauRx Therapeutics Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 50. TauRx Therapeutics Recent Developments and Future Plans

Table 51. Medtronic Company Information, Head Office, and Major Competitors

Table 52. Medtronic Major Business

Table 53. Medtronic Cognitive Decline Treatment Product and Solutions

Table 54. Medtronic Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 55. Medtronic Recent Developments and Future Plans

Table 56. Abbott Laboratories Company Information, Head Office, and Major Competitors

Table 57. Abbott Laboratories Major Business

Table 58. Abbott Laboratories Cognitive Decline Treatment Product and Solutions

Table 59. Abbott Laboratories Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 60. Abbott Laboratories Recent Developments and Future Plans

Table 61. Boston Scientific Company Information, Head Office, and Major Competitors

Table 62. Boston Scientific Major Business

Table 63. Boston Scientific Cognitive Decline Treatment Product and Solutions

Table 64. Boston Scientific Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 65. Boston Scientific Recent Developments and Future Plans

Table 66. NeuroPace Company Information, Head Office, and Major Competitors

Table 67. NeuroPace Major Business

Table 68. NeuroPace Cognitive Decline Treatment Product and Solutions

Table 69. NeuroPace Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 70. NeuroPace Recent Developments and Future Plans

Table 71. Posit Science Company Information, Head Office, and Major Competitors

Table 72. Posit Science Major Business

Table 73. Posit Science Cognitive Decline Treatment Product and Solutions

Table 74. Posit Science Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 75. Posit Science Recent Developments and Future Plans

Table 76. CogniFit Company Information, Head Office, and Major Competitors

Table 77. CogniFit Major Business

Table 78. CogniFit Cognitive Decline Treatment Product and Solutions

Table 79. CogniFit Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 80. CogniFit Recent Developments and Future Plans

Table 81. Linus Health Company Information, Head Office, and Major Competitors

Table 82. Linus Health Major Business

Table 83. Linus Health Cognitive Decline Treatment Product and Solutions

Table 84. Linus Health Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 85. Linus Health Recent Developments and Future Plans

Table 86. BrainCheck Company Information, Head Office, and Major Competitors

Table 87. BrainCheck Major Business

- Table 88. BrainCheck Cognitive Decline Treatment Product and Solutions
- Table 89. BrainCheck Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 90. BrainCheck Recent Developments and Future Plans
- Table 91. Eisai Company Information, Head Office, and Major Competitors
- Table 92. Eisai Major Business
- Table 93. Eisai Cognitive Decline Treatment Product and Solutions
- Table 94. Eisai Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 95. Eisai Recent Developments and Future Plans
- Table 96. Ono Pharmaceutical Company Information, Head Office, and Major Competitors
- Table 97. Ono Pharmaceutical Major Business
- Table 98. Ono Pharmaceutical Cognitive Decline Treatment Product and Solutions
- Table 99. Ono Pharmaceutical Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 100. Ono Pharmaceutical Recent Developments and Future Plans
- Table 101. Takeda Pharmaceutical Company Information, Head Office, and Major Competitors
- Table 102. Takeda Pharmaceutical Major Business
- Table 103. Takeda Pharmaceutical Cognitive Decline Treatment Product and Solutions
- Table 104. Takeda Pharmaceutical Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 105. Takeda Pharmaceutical Recent Developments and Future Plans
- Table 106. SK Biopharmaceuticals Company Information, Head Office, and Major Competitors
- Table 107. SK Biopharmaceuticals Major Business
- Table 108. SK Biopharmaceuticals Cognitive Decline Treatment Product and Solutions
- Table 109. SK Biopharmaceuticals Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 110. SK Biopharmaceuticals Recent Developments and Future Plans
- Table 111. VUNO Company Information, Head Office, and Major Competitors
- Table 112. VUNO Major Business
- Table 113. VUNO Cognitive Decline Treatment Product and Solutions
- Table 114. VUNO Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 115. VUNO Recent Developments and Future Plans
- Table 116. Ybrain Company Information, Head Office, and Major Competitors
- Table 117. Ybrain Major Business

- Table 118. Ybrain Cognitive Decline Treatment Product and Solutions
- Table 119. Ybrain Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 120. Ybrain Recent Developments and Future Plans
- Table 121. Green Valley Pharma Company Information, Head Office, and Major Competitors
- Table 122. Green Valley Pharma Major Business
- Table 123. Green Valley Pharma Cognitive Decline Treatment Product and Solutions
- Table 124. Green Valley Pharma Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 125. Green Valley Pharma Recent Developments and Future Plans
- Table 126. Neusoft Medical Company Information, Head Office, and Major Competitors
- Table 127. Neusoft Medical Major Business
- Table 128. Neusoft Medical Cognitive Decline Treatment Product and Solutions
- Table 129. Neusoft Medical Cognitive Decline Treatment Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 130. Neusoft Medical Recent Developments and Future Plans
- Table 131. Global Cognitive Decline Treatment Revenue (USD Million) by Players (2021-2026)
- Table 132. Global Cognitive Decline Treatment Revenue Share by Players (2021-2026)
- Table 133. Breakdown of Cognitive Decline Treatment by Company Type (Tier 1, Tier 2, and Tier 3)
- Table 134. Market Position of Players in Cognitive Decline Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
- Table 135. Head Office of Key Cognitive Decline Treatment Players
- Table 136. Cognitive Decline Treatment Market: Company Product Type Footprint
- Table 137. Cognitive Decline Treatment Market: Company Product Application Footprint
- Table 138. Cognitive Decline Treatment New Market Entrants and Barriers to Market Entry
- Table 139. Cognitive Decline Treatment Mergers, Acquisition, Agreements, and Collaborations
- Table 140. Global Cognitive Decline Treatment Consumption Value (USD Million) by Type (2021-2026)
- Table 141. Global Cognitive Decline Treatment Consumption Value Share by Type (2021-2026)
- Table 142. Global Cognitive Decline Treatment Consumption Value Forecast by Type (2027-2032)
- Table 143. Global Cognitive Decline Treatment Consumption Value by Application (2021-2026)

Table 144. Global Cognitive Decline Treatment Consumption Value Forecast by Application (2027-2032)

Table 145. North America Cognitive Decline Treatment Consumption Value by Type (2021-2026) & (USD Million)

Table 146. North America Cognitive Decline Treatment Consumption Value by Type (2027-2032) & (USD Million)

Table 147. North America Cognitive Decline Treatment Consumption Value by Application (2021-2026) & (USD Million)

Table 148. North America Cognitive Decline Treatment Consumption Value by Application (2027-2032) & (USD Million)

Table 149. North America Cognitive Decline Treatment Consumption Value by Country (2021-2026) & (USD Million)

Table 150. North America Cognitive Decline Treatment Consumption Value by Country (2027-2032) & (USD Million)

Table 151. Europe Cognitive Decline Treatment Consumption Value by Type (2021-2026) & (USD Million)

Table 152. Europe Cognitive Decline Treatment Consumption Value by Type (2027-2032) & (USD Million)

Table 153. Europe Cognitive Decline Treatment Consumption Value by Application (2021-2026) & (USD Million)

Table 154. Europe Cognitive Decline Treatment Consumption Value by Application (2027-2032) & (USD Million)

Table 155. Europe Cognitive Decline Treatment Consumption Value by Country (2021-2026) & (USD Million)

Table 156. Europe Cognitive Decline Treatment Consumption Value by Country (2027-2032) & (USD Million)

Table 157. Asia-Pacific Cognitive Decline Treatment Consumption Value by Type (2021-2026) & (USD Million)

Table 158. Asia-Pacific Cognitive Decline Treatment Consumption Value by Type (2027-2032) & (USD Million)

Table 159. Asia-Pacific Cognitive Decline Treatment Consumption Value by Application (2021-2026) & (USD Million)

Table 160. Asia-Pacific Cognitive Decline Treatment Consumption Value by Application (2027-2032) & (USD Million)

Table 161. Asia-Pacific Cognitive Decline Treatment Consumption Value by Region (2021-2026) & (USD Million)

Table 162. Asia-Pacific Cognitive Decline Treatment Consumption Value by Region (2027-2032) & (USD Million)

Table 163. South America Cognitive Decline Treatment Consumption Value by Type

(2021-2026) & (USD Million)

Table 164. South America Cognitive Decline Treatment Consumption Value by Type (2027-2032) & (USD Million)

Table 165. South America Cognitive Decline Treatment Consumption Value by Application (2021-2026) & (USD Million)

Table 166. South America Cognitive Decline Treatment Consumption Value by Application (2027-2032) & (USD Million)

Table 167. South America Cognitive Decline Treatment Consumption Value by Country (2021-2026) & (USD Million)

Table 168. South America Cognitive Decline Treatment Consumption Value by Country (2027-2032) & (USD Million)

Table 169. Middle East & Africa Cognitive Decline Treatment Consumption Value by Type (2021-2026) & (USD Million)

Table 170. Middle East & Africa Cognitive Decline Treatment Consumption Value by Type (2027-2032) & (USD Million)

Table 171. Middle East & Africa Cognitive Decline Treatment Consumption Value by Application (2021-2026) & (USD Million)

Table 172. Middle East & Africa Cognitive Decline Treatment Consumption Value by Application (2027-2032) & (USD Million)

Table 173. Middle East & Africa Cognitive Decline Treatment Consumption Value by Country (2021-2026) & (USD Million)

Table 174. Middle East & Africa Cognitive Decline Treatment Consumption Value by Country (2027-2032) & (USD Million)

Table 175. Global Key Players of Cognitive Decline Treatment Upstream (Raw Materials)

Table 176. Global Cognitive Decline Treatment Typical Customers

## List Of Figures

### LIST OF FIGURES

- Figure 1. Cognitive Decline Treatment Picture
- Figure 2. Global Cognitive Decline Treatment Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
- Figure 3. Global Cognitive Decline Treatment Consumption Value Market Share by Type in 2025
- Figure 4. Prescription Drugs
- Figure 5. Medical Devices
- Figure 6. Digital Therapy Software
- Figure 7. Rehabilitation Training Services
- Figure 8. Others
- Figure 9. Global Cognitive Decline Treatment Consumption Value by Intervention Stages, (USD Million), 2021 & 2025 & 2032
- Figure 10. Global Cognitive Decline Treatment Consumption Value Market Share by Intervention Stages in 2025
- Figure 11. Prevention Stage
- Figure 12. Early Intervention
- Figure 13. Intermediate Treatment
- Figure 14. Late-Stage Supportive Treatment
- Figure 15. Global Cognitive Decline Treatment Consumption Value by Technological Pathways, (USD Million), 2021 & 2025 & 2032
- Figure 16. Global Cognitive Decline Treatment Consumption Value Market Share by Technological Pathways in 2025
- Figure 17. Neurotransmitter Regulation Pathway
- Figure 18. Amyloid (A?) Clearance Pathway
- Figure 19. Tau Protein Targeting Pathway
- Figure 20. Neuroinflammatory Regulation Pathway
- Figure 21. Neuroplasticity Enhancement Pathway
- Figure 22. Global Cognitive Decline Treatment Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
- Figure 23. Cognitive Decline Treatment Consumption Value Market Share by Application in 2025
- Figure 24. Alzheimer's Disease (AD) Picture
- Figure 25. Vascular Cognitive Impairment (VCI) Picture
- Figure 26. Parkinson's-Related Cognitive Decline Picture
- Figure 27. Post-Traumatic Brain Injury Cognitive Impairment Picture

Figure 28. Mild Cognitive Impairment (MCI) Picture

Figure 29. Global Cognitive Decline Treatment Consumption Value, (USD Million): 2021 & 2025 & 2032

Figure 30. Global Cognitive Decline Treatment Consumption Value and Forecast (2021-2032) & (USD Million)

Figure 31. Global Market Cognitive Decline Treatment Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)

Figure 32. Global Cognitive Decline Treatment Consumption Value Market Share by Region (2021-2032)

Figure 33. Global Cognitive Decline Treatment Consumption Value Market Share by Region in 2025

Figure 34. North America Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)

Figure 35. Europe Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)

Figure 36. Asia-Pacific Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)

Figure 37. South America Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)

Figure 38. Middle East & Africa Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)

Figure 39. Company Three Recent Developments and Future Plans

Figure 40. Global Cognitive Decline Treatment Revenue Share by Players in 2025

Figure 41. Cognitive Decline Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025

Figure 42. Market Share of Cognitive Decline Treatment by Player Revenue in 2025

Figure 43. Top 3 Cognitive Decline Treatment Players Market Share in 2025

Figure 44. Top 6 Cognitive Decline Treatment Players Market Share in 2025

Figure 45. Global Cognitive Decline Treatment Consumption Value Share by Type (2021-2026)

Figure 46. Global Cognitive Decline Treatment Market Share Forecast by Type (2027-2032)

Figure 47. Global Cognitive Decline Treatment Consumption Value Share by Application (2021-2026)

Figure 48. Global Cognitive Decline Treatment Market Share Forecast by Application (2027-2032)

Figure 49. North America Cognitive Decline Treatment Consumption Value Market Share by Type (2021-2032)

Figure 50. North America Cognitive Decline Treatment Consumption Value Market

Share by Application (2021-2032)

Figure 51. North America Cognitive Decline Treatment Consumption Value Market

Share by Country (2021-2032)

Figure 52. United States Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)

Figure 53. Canada Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)

Figure 54. Mexico Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)

Figure 55. Europe Cognitive Decline Treatment Consumption Value Market Share by Type (2021-2032)

Figure 56. Europe Cognitive Decline Treatment Consumption Value Market Share by Application (2021-2032)

Figure 57. Europe Cognitive Decline Treatment Consumption Value Market Share by Country (2021-2032)

Figure 58. Germany Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)

Figure 59. France Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)

Figure 60. United Kingdom Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)

Figure 61. Russia Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)

Figure 62. Italy Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)

Figure 63. Asia-Pacific Cognitive Decline Treatment Consumption Value Market Share by Type (2021-2032)

Figure 64. Asia-Pacific Cognitive Decline Treatment Consumption Value Market Share by Application (2021-2032)

Figure 65. Asia-Pacific Cognitive Decline Treatment Consumption Value Market Share by Region (2021-2032)

Figure 66. China Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)

Figure 67. Japan Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)

Figure 68. South Korea Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)

Figure 69. India Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)

- Figure 70. Southeast Asia Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)
- Figure 71. Australia Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)
- Figure 72. South America Cognitive Decline Treatment Consumption Value Market Share by Type (2021-2032)
- Figure 73. South America Cognitive Decline Treatment Consumption Value Market Share by Application (2021-2032)
- Figure 74. South America Cognitive Decline Treatment Consumption Value Market Share by Country (2021-2032)
- Figure 75. Brazil Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)
- Figure 76. Argentina Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)
- Figure 77. Middle East & Africa Cognitive Decline Treatment Consumption Value Market Share by Type (2021-2032)
- Figure 78. Middle East & Africa Cognitive Decline Treatment Consumption Value Market Share by Application (2021-2032)
- Figure 79. Middle East & Africa Cognitive Decline Treatment Consumption Value Market Share by Country (2021-2032)
- Figure 80. Turkey Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)
- Figure 81. Saudi Arabia Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)
- Figure 82. UAE Cognitive Decline Treatment Consumption Value (2021-2032) & (USD Million)
- Figure 83. Cognitive Decline Treatment Market Drivers
- Figure 84. Cognitive Decline Treatment Market Restraints
- Figure 85. Cognitive Decline Treatment Market Trends
- Figure 86. Porters Five Forces Analysis
- Figure 87. Cognitive Decline Treatment Industrial Chain
- Figure 88. Methodology
- Figure 89. Research Process and Data Source

## I would like to order

Product name: Global Cognitive Decline Treatment Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Product link: <https://marketpublishers.com/r/G630B815E3C3EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G630B815E3C3EN.html>